Kristi Rosa

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.

The EMA’s CHMP has adopted a positive opinion regarding frontline nivolumab plus ipilimumab in unresectable or advanced hepatocellular carcinoma.

The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.

Trifluridine/tipiracil showed a numerical, but not significant, DFS improvement in all patients with residual disease after curative resection of CRC.

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

Pelareorep plus modified FOLFIRINOX with or without atezolizumab showed acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.

Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.

Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Nogapendekin alfa inbakicept MAAs have been submitted to the EU's EMA and the UK's MHRA for BCG-unresponsive non–muscle-invasive bladder cancer.

OST-HER2 shows promise in patients with recurrent, fully resected lung-only metastatic osteosarcoma.

Tisotumab vedotin led to improved survival vs chemotherapy in a Chinese subpopulation of previously treated cervical cancer enrolled in innovaTV 301.

Sunvozertinib gets priority review in EGFR-mutated NSCLC, iparomlimab/tuvonralimab combination elicits responses in cervical cancer, and more.

Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.

An acalabrutinib triplet elicited a high response rate in patients with de novo mantle cell lymphoma.

An investigative JAK2 inhibitor demonstrated acceptable tolerability and early clinical activity in patients with JAK inhibitor–naive myelofibrosis.

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.